A Comparative Real‐World Study Evaluating the Safety of Immune Globulin Infusion (Human) 10% Solution and Other Intravenous Immunoglobulin Therapies for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Pharmacoepidemiology and Drug Safety · 2025
DOI: 10.1002/pds.70124 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von J Bradley Layton und 8 weiteren Autor:innen. Beteiligte Einrichtung: RTI Health Solutions, Research Triangle Park, North Carolina, USA. Hauptthemen laut MEDLINE: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Immunoglobulins, Intravenous. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Development Center Americas, Inc.
Abstract (Originalsprache)
Purpose
Immune globulin infusion (human) 10% solution (GAMMAGARD LIQUID; GGL), an intravenous immunoglobulin (IVIG), has recently received U.S. approval for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). We evaluated thrombotic events, acute kidney injury (AKI), and hemolytic events among patients with CIDP initiating IVIG treatment with GGL, versus a U.S.‐approved IVIG comparator for CIDP, in individual and combined cohorts of immunoglobulin (Ig)‐naive and Ig‐experienced participants.
Methods
This active‐comparator, new‐user, cohort study of patients with CIDP used the Merative MarketScan Research and Optum Clinformatics Data Mart databases (2008–2019). Outcomes were compared between adults receiving GGL and comparator IVIGs within propensity score‐weighted samples using hazard ratios (HRs) and time period‐specific risk ratios (RRs) and risk differences (RDs) with 95% confidence intervals (CI). Database‐specific results were meta‐analyzed and appropriate.
Results
Data from eligible patients in MarketScan (GGL, n = 1441; comparators, n = 2708) and Optum (GGL, n = 644; comparators, n = 1293) were analyzed. Across both databases, HRs, 1‐year RRs, and 1‐year RDs for thrombotic events did not suggest consistent differences in risk across treatment groups (e.g., MarketScan combined cohort: RR 1.14 [95% CI, 0.50 to 2.55]; Optum combined cohort: 0.60 [0.25 to 1.54]). Similarly, there was no difference in AKI risk between groups (e.g., MarketScan combined cohort: RR 1.25 [95% CI, 0.65 to 2.54]; Optum combined cohort: 0.65 [0.22 to 1.94]). Hemolytic events were rare.
Conclusions
Thrombotic events, AKI, and hemolytic events were rare among patients with CIDP receiving IVIG. There were no consistently different outcome risks between patients receiving GGL versus other IVIGs with US approval for CIDP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- RTI Health Solutions, Research Triangle Park, North Carolina, USA.
- Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA.
ORCID-Profile: J Bradley Layton, Colin Anderson-Smits, Mary S Anthony
Förderung
- Takeda Development Center Americas, Inc
Zitieren
APA
Layton, J. B., Anderson-Smits, C., Huang, Z., Ay, H., Spalding, W., Khokhar, B., Zhou, J., Bennett, L., & Anthony, M. S. (2025). A Comparative Real‐World Study Evaluating the Safety of Immune Globulin Infusion (Human) 10% Solution and Other Intravenous Immunoglobulin Therapies for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70124
Vancouver
Layton JB, Anderson-Smits C, Huang Z, Ay H, Spalding W, Khokhar B, et al. A Comparative Real‐World Study Evaluating the Safety of Immune Globulin Infusion (Human) 10% Solution and Other Intravenous Immunoglobulin Therapies for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70124
BibTeX
@article{Layton2025,
author = {Layton, J Bradley and Anderson-Smits, Colin and Huang, Zhongwen and Ay, Hakan and Spalding, William and Khokhar, Bilal and Zhou, Jie and Bennett, Lee and Anthony, Mary S},
title = {A Comparative Real‐World Study Evaluating the Safety of Immune Globulin Infusion (Human) 10% Solution and Other Intravenous Immunoglobulin Therapies for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2025},
doi = {10.1002/pds.70124}
}
EUVIMED